DBV Technologies SA - Company Profile (NASDAQ:DBVT)

About DBV Technologies SA - (NASDAQ:DBVT)

DBV Technologies SA - logoDBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DBVT
  • CUSIP: N/A
  • Web: www.dbv-technologies.com
Capitalization:
  • Market Cap: $1.57 billion
  • Outstanding Shares: 46,000,000
Average Prices:
  • 50 Day Moving Avg: $34.25
  • 200 Day Moving Avg: $35.11
  • 52 Week Range: $27.02 - $37.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.72
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.21 million
  • Price / Sales: 190.72
  • Book Value: $5.37 per share
  • Price / Book: 6.34
Profitability:
  • EBIDTA: ($125,100,000.00)
Misc:
  • Average Volume: 78,711 shs.
  • Beta: 1.47
  • Short Ratio: 3.58
 

Frequently Asked Questions for DBV Technologies SA - (NASDAQ:DBVT)

What is DBV Technologies SA -'s stock symbol?

DBV Technologies SA - trades on the NASDAQ under the ticker symbol "DBVT."

How were DBV Technologies SA -'s earnings last quarter?

DBV Technologies SA - (NASDAQ:DBVT) announced its earnings results on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.35. View DBV Technologies SA -'s Earnings History.

Where is DBV Technologies SA -'s stock going? Where will DBV Technologies SA -'s stock price be in 2017?

5 brokerages have issued 1-year price objectives for DBV Technologies SA -'s shares. Their forecasts range from $47.00 to $54.00. On average, they anticipate DBV Technologies SA -'s share price to reach $49.33 in the next year. View Analyst Ratings for DBV Technologies SA -.

Are investors shorting DBV Technologies SA -?

DBV Technologies SA - saw a increase in short interest in March. As of March 31st, there was short interest totalling 351,187 shares, an increase of 9.0% from the March 15th total of 322,303 shares. Based on an average daily volume of 70,825 shares, the short-interest ratio is currently 5.0 days.

Who are some of DBV Technologies SA -'s key competitors?

Who owns DBV Technologies SA - stock?

DBV Technologies SA -'s stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (7.12%), Janus Capital Management LLC (5.45%), Alliancebernstein L.P. (2.17%), TimesSquare Capital Management LLC (2.08%), Perceptive Advisors LLC (1.29%) and Jennison Associates LLC (1.17%). View Institutional Ownership Trends for DBV Technologies SA -.

Who sold DBV Technologies SA - stock? Who is selling DBV Technologies SA - stock?

DBV Technologies SA -'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Manhattan Co., Janus Capital Management LLC, Eventide Asset Management LLC, TimesSquare Capital Management LLC, Artisan Partners Limited Partnership, Perceptive Advisors LLC and Tocqueville Asset Management L.P.. View Insider Buying and Selling for DBV Technologies SA -.

Who bought DBV Technologies SA - stock? Who is buying DBV Technologies SA - stock?

DBV Technologies SA -'s stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Morgan Stanley, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Point72 Asset Management L.P., Hikari Power Ltd, Jane Street Group LLC and Simplex Trading LLC. View Insider Buying and Selling for DBV Technologies SA -.

How do I buy DBV Technologies SA - stock?

Shares of DBV Technologies SA - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of DBV Technologies SA - stock cost?

One share of DBV Technologies SA - stock can currently be purchased for approximately $34.04.

Analyst Ratings

Consensus Ratings for DBV Technologies SA - (NASDAQ:DBVT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $49.33 (44.93% upside)

Analysts' Ratings History for DBV Technologies SA - (NASDAQ:DBVT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/15/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
3/16/2017Jefferies Group LLCReiterated RatingBuy$47.00MediumView Rating Details
3/16/2017Societe GeneraleUpgradeHold -> BuyMediumView Rating Details
2/17/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$47.00N/AView Rating Details
3/16/2016Citigroup IncLower Price TargetBuy$48.00 -> $43.00N/AView Rating Details
3/7/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
12/3/2015Barclays PLCInitiated CoveragePositive -> Overweight$58.00N/AView Rating Details
10/23/2015Bank of America CorpInitiated CoverageBuy$48.00N/AView Rating Details
9/15/2015Morgan StanleyInitiated CoverageOverweight$59.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for DBV Technologies SA - (NASDAQ:DBVT)
Earnings by Quarter for DBV Technologies SA - (NASDAQ:DBVT)
Earnings History by Quarter for DBV Technologies SA - (NASDAQ:DBVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2015($0.44)($0.79)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for DBV Technologies SA - (NASDAQ:DBVT)
2017 EPS Consensus Estimate: ($4.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($1.00)($1.00)($1.00)
Q3 20171($1.04)($1.04)($1.04)
Q4 20171($1.05)($1.05)($1.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for DBV Technologies SA - (NASDAQ:DBVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for DBV Technologies SA - (NASDAQ:DBVT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for DBV Technologies SA - (NASDAQ:DBVT)
Latest Headlines for DBV Technologies SA - (NASDAQ:DBVT)
Source:
DateHeadline
americanbankingnews.com logoDBV Technologies SA - (DBVT) Expected to Earn Q2 2017 Earnings of ($1.00) Per Share
www.americanbankingnews.com - May 22 at 7:12 AM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 12:12 AM
finance.yahoo.com logoDBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017
finance.yahoo.com - May 8 at 9:29 AM
americanbankingnews.com logo Brokerages Expect DBV Technologies SA - (DBVT) to Announce -$0.91 Earnings Per Share
www.americanbankingnews.com - May 1 at 10:07 AM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Earning Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 29 at 9:02 AM
finance.yahoo.com logoDBV Technologies Reports March 31, 2017 Cash Position
finance.yahoo.com - April 28 at 3:14 AM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 12:53 AM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 24 at 7:14 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Short Interest Update
www.americanbankingnews.com - April 24 at 5:53 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Given Daily Media Impact Score of 0.31
www.americanbankingnews.com - April 23 at 6:35 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Receiving Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 20 at 4:56 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Earns Daily Coverage Optimism Score of 0.56
www.americanbankingnews.com - April 17 at 12:28 PM
americanbankingnews.com logoZacks: Brokerages Expect DBV Technologies SA - (DBVT) Will Post Earnings of -$0.91 Per Share
www.americanbankingnews.com - April 8 at 12:22 AM
finance.yahoo.com logoDBV Technologies to Attend the 10th Kempen Life Sciences Conference
finance.yahoo.com - April 7 at 9:23 AM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 6 at 5:49 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 7:20 AM
americanbankingnews.com logoZacks Investment Research Upgrades DBV Technologies SA - (DBVT) to "Hold"
www.americanbankingnews.com - March 31 at 5:40 PM
finance.yahoo.com logoDBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
finance.yahoo.com - March 30 at 5:06 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 30 at 1:43 PM
finance.yahoo.com logoDBV TECHNOLOGIES S.A. Financials
finance.yahoo.com - March 28 at 4:24 PM
americanbankingnews.com logoDBV Technologies SA - (DBVT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 7:18 PM
americanbankingnews.com logoJefferies Group Equities Analysts Decrease Earnings Estimates for DBV Technologies SA - (DBVT)
www.americanbankingnews.com - March 20 at 11:38 AM
americanbankingnews.com logoFY2017 Earnings Forecast for DBV Technologies SA - Issued By Leerink Swann (DBVT)
www.americanbankingnews.com - March 20 at 11:38 AM
us.rd.yahoo.com logoDBV Technologies upgraded by Societe Generale
us.rd.yahoo.com - March 16 at 6:04 PM
finance.yahoo.com logoDBV Technologies Reports Full Year 2016 Financial Results
finance.yahoo.com - March 15 at 9:58 AM
finance.yahoo.com logoDBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
finance.yahoo.com - March 10 at 3:21 AM
us.rd.yahoo.com logoA patch could fix your peanut-allergy problem
us.rd.yahoo.com - March 7 at 9:39 PM
finance.yahoo.com logoDBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
finance.yahoo.com - March 5 at 4:34 PM
finance.yahoo.com logoDBV Technologies Reports December 31, 2016 Cash Position
finance.yahoo.com - February 20 at 11:34 AM
finance.yahoo.com logoDBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®
finance.yahoo.com - February 18 at 8:25 AM
us.rd.yahoo.com logo3:10 am DBV Technologies completes enrollment of Phase IIA study of Viaskin Milk; expects results in 1H18
us.rd.yahoo.com - February 3 at 10:03 PM
finance.yahoo.com logoDBV Technologies Announces Financial Calendar 2017
finance.yahoo.com - January 9 at 2:37 AM
finance.yahoo.com logoDBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
finance.yahoo.com - January 4 at 5:44 PM
finance.yahoo.com logoDBV Technologies presents its Half-year Statement of the Liquidity Contract
finance.yahoo.com - January 4 at 5:44 PM
finance.yahoo.com logoDBV Technologies :Monthly information regarding the total number of voting rights and total number of shares of the Company
finance.yahoo.com - December 7 at 3:53 PM
finance.yahoo.com logoLysogene Appoints David Schilansky to Board of Directors
finance.yahoo.com - December 7 at 9:47 AM
us.rd.yahoo.com logoDBV Technologies SA – ADR (DBVT): Smart Money Is Slowly Coming Back
us.rd.yahoo.com - December 5 at 12:06 PM
nasdaq.com logoIs DBV Technologies (DBVT) Stock a Solid Choice Right Now? - Nasdaq
www.nasdaq.com - December 2 at 4:58 PM
finance.yahoo.com logoIs DBV Technologies (DBVT) Stock a Solid Choice Right Now?
finance.yahoo.com - December 1 at 4:47 PM
finance.yahoo.com logoDBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
finance.yahoo.com - November 20 at 8:43 AM
streetinsider.com logoForm 6-K DBV Technologies SA For: Nov 17 - StreetInsider.com
www.streetinsider.com - November 17 at 3:50 PM
finance.yahoo.com logoDBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting
finance.yahoo.com - November 11 at 9:49 PM
finance.yahoo.com logoBlog Coverage DBV Technologies Executes Phase II Study of VIASKIN Milk for Treatment of Milk Allergic Patients
finance.yahoo.com - November 9 at 1:46 PM
streetinsider.com logoForm 6-K DBV Technologies SA For: Nov 08 - StreetInsider.com
www.streetinsider.com - November 8 at 10:57 AM
streetinsider.com logoForm 6-K DBV Technologies SA For: Nov 03 - StreetInsider.com
www.streetinsider.com - November 4 at 11:53 AM
finance.yahoo.com logoThere's a patch that could fix your peanut allergy problem
finance.yahoo.com - November 1 at 4:46 PM
finance.yahoo.com logoDBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology
finance.yahoo.com - October 26 at 4:38 PM
finance.yahoo.com logoDBV Technologies: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
finance.yahoo.com - October 25 at 9:25 AM
finance.yahoo.com logo4:32 pm DBV Technologies announces topline results from the two-year OLFUS-VIPES study supporting the durable effect and favorable safety profile of Viaskin Peanut for the treatment of peanut-allergic children
finance.yahoo.com - October 25 at 9:25 AM
finance.yahoo.com logoCoverage initiated on DBV Technologies by JMP Securities
finance.yahoo.com - September 26 at 4:46 PM

Social

DBV Technologies SA - (DBVT) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff